Japanese Pharmas Compete In Race For Flu-Pandemic Drug
This article was originally published in PharmAsia News
Japanese pharmaceutical companies are racing to develop drugs to fight a possible flu pandemic, with several firms in various stages of drug development. Tohama Chemical already has begun clinical trials of a compound it hopes to have on the market in April 2009, and Daiichi Sankyo has trials underway on an antiviral that is inhaled. Taiko Pharmaceutical takes a far different route with some over-the-counter treatments. Although antivirals are considered the strongest defenses against a pandemic, the common process of producing them remains a hurdle for the industry, which needs to be able to produce enough drugs quickly once the source virus is identified. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.